We highlighted Moderna (MRNA) has an opportunity at $72 a share. It’s now set to open at $97.25 this morning.
We highlighted AstraZeneca (AZN) on Friday as it traded at $57.65. It’s now set to open at $61.90. We highlighted Pfizer (PFE) at $34.63. It’s now set to open at $37.57 this morning.
And we highlighted BioNTech (BNTX) at $78.38. It’s now set to open at $93.80.
If you were in these trades, we’d love to hear how you’re doing so far.
Sticking with the coronavirus theme, consider Vaxart Inc. (VXRT), which hopes to advance its Phase 1 clinical trials later this year. If the company sees solid success, it could easily double, if not triple going forward, in our opinion.
Just recently, the company was selected to participate in a non-human primate (NHP) challenge study, organized and funded by Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021.
“We are very pleased to be one of the few companies selected by Operation Warp Speed, and that ours is the only oral vaccine being evaluated. SARS-CoV-2, the coronavirus that causes COVID-19, is primarily transmitted by viral particles that enter through the mucosa – nose, mouth or eyes – strongly suggesting that mucosal immunity could serve as the first line of defense,” said Andrei Floroiu, CEO of Vaxart Inc. in a company press release.